Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

CEO

Dr. Joseph A. Wiley

Employees

182

Country

United Kingdom

ISIN

US03217L1061

Listings

STU

3N9A.STU

0 Comments

Share your thoughts

FAQ

What is Amryt Pharma stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Amryt Pharma stocks are traded under the ticker 3N9A.STU.

How many employees does Amryt Pharma have?▼

As of July 26, 2026, the company has 182 employees.

In which sector is Amryt Pharma located?▼

Amryt Pharma operates in the Health & Wellness sector.

When did Amryt Pharma complete a stock split?▼

Amryt Pharma has not had any recent stock splits.

Where is Amryt Pharma headquartered?▼

Amryt Pharma is headquartered in Dublin, United Kingdom.